Yu Xinxin, Chen Shiuhwei, Funcke Jan-Bernd, Straub Leon G, Pirro Valentina, Emont Margo P, Droz Brian A, Collins Kyla Ai, Joung Chanmin, Pearson Mackenzie J, James Corey M, Babu Gopal J, Efthymiou Vissarion, Vernon Ashley, Patti Mary Elizabeth, An Yu A, Rosen Evan D, Coghlan Matthew P, Samms Ricardo J, Scherer Philipp E, Kusminski Christine M
Touchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Eli Lilly Research Laboratories, Division of Eli Lilly and Company, Indianapolis, IN 46285, USA.
Cell Metab. 2025 Jan 7;37(1):187-204.e7. doi: 10.1016/j.cmet.2024.11.003. Epub 2024 Dec 5.
Obesity is a chronic disease that contributes to the development of insulin resistance, type 2 diabetes (T2D), and cardiovascular risk. Glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) and glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) co-agonism provide an improved therapeutic profile in individuals with T2D and obesity when compared with selective GLP-1R agonism. Although the metabolic benefits of GLP-1R agonism are established, whether GIPR activation impacts weight loss through peripheral mechanisms is yet to be fully defined. Here, we generated a mouse model of GIPR induction exclusively in the adipocyte. We show that GIPR induction in the fat cell protects mice from diet-induced obesity and triggers profound weight loss (∼35%) in an obese setting. Adipose GIPR further increases lipid oxidation, thermogenesis, and energy expenditure. Mechanistically, we demonstrate that GIPR induction activates SERCA-mediated futile calcium cycling in the adipocyte. GIPR activation further triggers a metabolic memory effect, which maintains weight loss after the transgene has been switched off, highlighting a unique aspect in adipocyte biology. Collectively, we present a mechanism of peripheral GIPR action in adipose tissue, which exerts beneficial metabolic effects on body weight and energy balance.
肥胖是一种慢性疾病,会导致胰岛素抵抗、2型糖尿病(T2D)以及心血管风险的发展。与选择性胰高血糖素样肽-1受体(GLP-1R)激动剂相比,葡萄糖依赖性促胰岛素多肽(GIP)受体(GIPR)和GLP-1R共同激动剂在T2D和肥胖个体中具有更好的治疗效果。尽管GLP-1R激动剂的代谢益处已得到证实,但GIPR激活是否通过外周机制影响体重减轻尚未完全明确。在此,我们构建了仅在脂肪细胞中诱导GIPR的小鼠模型。我们发现脂肪细胞中GIPR的诱导可保护小鼠免受饮食诱导的肥胖,并在肥胖状态下引发显著的体重减轻(约35%)。脂肪组织中的GIPR进一步增加脂质氧化、产热和能量消耗。从机制上讲,我们证明GIPR的诱导激活了脂肪细胞中受磷蛋白(SERCA)介导的无效钙循环。GIPR激活还会触发一种代谢记忆效应,在转基因关闭后仍能维持体重减轻,突出了脂肪细胞生物学的一个独特方面。总体而言,我们提出了脂肪组织中GIPR外周作用的机制,其对体重和能量平衡产生有益的代谢影响。